The co-occurrence of biomarkers and cancer concepts in immuno-oncology publications underscores the complexity and interdependence of immune responses and cancer biology. Advanced analytical techniques are essential for uncovering these relationships, ultimately leading to more effective and personalized cancer immunotherapies. • TMB | Colon cancer; TMB | CRC Tumor Mutational Burden (TMB) is a biomarker that quantifies the number of mutations within a tumor genome. It is gaining importance in immuno-oncology as a predictor of response to ICIs. High TMB is associated with a higher likelihood of producing neoantigens, which can make tumors more recognizable and targetable by the immune system. High TMB leads to the production of neoantigens, which are novel protein sequences arising from tumor-specific mutations. These neoantigens can be recognized as foreign by the immune system, prompting an immune response. ICIs, such as PD-1/PD-L1 inhibitors, work by unleashing the immune system to attack cancer cells.